Adult Schizophrenia Drug Wins FDA Approval
Teva Pharmaceuticals and MedinCell recently received approval from the U.S. Food and Drug Administration (FDA) for UZEDY™ (risperidone).
Penn Medicine Magazine Showcases Penn’s Drug Research and Development and Commercial Partnerships
The Spring 2023 issue of Penn Medicine Magazine describes how Penn has become a hub for drug research and development and created the infrastructure in both supporting clinical research and forging co
Technology to help Newborns in the NICU wins 2023 President’s Innovation Prize
Penn President Liz Magill awarded the 2023 President’s Innovation Prize toGabriella Daltoso, Sophie Ishiwari, Gabriela Cano, Caroline Amanda Magro, and Tifara Eliana Boyce for their project, Sonura.
Bruce Levine Speaks on the Future of CAR-T Therapies
Levine explained that there are currently six approved CAR-T therapies and he estimates that between 25,000 and 30,000 patients have been treated with those therapies globally.
Ligand-tethered Lipid Nanoparticles for Targeted RNA Delivery to Treat Liver Fibrosis
the Mitchell Lab has developed a new class of anisimide-functionalized lipids that enables targeted delivery of lipid nanoparticles (LNPs) to activated fibroblasts in the liver.
Fake
This technology is an intracerebral drug delivery system that consists of three flexible, retractable microcannulas housed within a single central catheter.
Mitchell Lab’s Targeted Prenatal Therapy for Mothers and Their Babies Addresses Gap in Health Equity
The researchers’ successful trials in mice show that the technology may potentially lead to promising treatment options for humans with pre-eclampsia.
Penn Medicine, CHOP receive $25M anonymous gift to accelerate research in rare genetic brain disorders
The donation will establish the Center for Epilepsy and Neurodevelopmental Disorders, which will initially focus on developing therapies for disorders related to genetic mutations that are linked to a
Eidos LGBTQ+ Health Initiative Support Advances in LGBTQIA+ Health Startups
The goal of the partnership is to support founders and entrepreneurs with in-depth LGBTQ+ health knowledge and research expertise.